Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Sarcoma 2

Conditions

Leukemia 22Lymphoma 14Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 12Leukemia, Lymphocytic, Chronic, B-Cell 12Breast Neoplasms 11Prostatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Multiple Myeloma 9Melanoma 9Lymphoma, Follicular 9Neuroblastoma 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Ovarian Neoplasms 7Congenital Abnormalities 7Lymphoma, Non-Hodgkin 6Hodgkin Disease 5Neoplasms, Plasma Cell 4Neoplasm Metastasis 4Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Chronic-Phase 4Glioblastoma 4Fallopian Tube Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Waldenstrom Macroglobulinemia 3Osteosarcoma 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

Temozolomide 115Bevacizumab 72Radiotherapy 52Radiation 23Erlotinib Hydrochloride 13Lomustine 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Vorinostat 10Nivolumab 10Surgical Procedures, Operative 9Irinotecan 9Sorafenib 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 7Immunoglobulin G 7Everolimus 7Drug Therapy 7Disulfides 7Radiosurgery 6Granulocyte-Macrophage Colony-Stimulating Factor 6Carmustine 6antineoplaston AS 2-1 5antineoplaston A10 5Sirolimus 5Cilengitide 5veliparib 4veledimex 4temsirolimus 4selinexor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Glioblastoma × sargramostim × Clear all
NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Roswell Park Cancer Institute

Phase 2 Active not recruiting
66 enrolled 11 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04013672 2024-08-28

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Case Comprehensive Cancer Center

Phase 2 Completed
41 enrolled 15 charts
CNS

Glioblastoma

NCT03927222 2024-04-08

I-ATTAC

Duke University

Phase 2 Terminated
6 enrolled 7 charts
CNS

Glioblastoma, Tetanus

NCT00643097 2017-02-01

ACTIVATe

Duke University

Phase 2 Completed
40 enrolled 9 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡